Zacks Investment Research on MSN
ALT stock up 17% after pemvidutide gets FDA breakthrough tag for MASH
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...
Woman's World on MSN
Normal AST levels by age: Are you at risk of fatty liver disease?
A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...
Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for ...
Altimmune Inc (NASDAQ:ALT) shares jumped 8.5% to $5.61 on Friday, ahead of next week’s presentation at the European Association for the Study of the Liver International Liver Congress 2025. The stock ...
On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Treatment discontinuation ...
GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Having persistently high liver enzyme levels present in early adulthood is a strong predictor of type 2 diabetes risk. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback